Overview

Fenoldopam for Prevention of Acute Kidney Injury

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:
0

Participant gender:
All

Summary

Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury (AKI) when they undergo urgent/emergency coronary angiography. The optimal medical treatment for preventing the occurrence of contrast induced - acute kidney injury is still controversial. Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary studies. Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI already shown to be useful for earlier diagnosis of contrast induced nephropathy. The primary objective of this study is to to test the hypothesis that fenoldopam, in addition to standard treatment, reduce the occurrence of contrast induced - acute kidney injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary angiography and/or percutaneous coronary intervention.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Roma La Sapienza

Treatments:

Fenoldopam

Criteria

Inclusion Criteria:

- Indication to urgent/emergency coronary angiography

- Normal renal function (eGFR> 60 ml/min/1.73 m2)

- Moderate or high Mehran's risk score for CIN (>11).

- Able to understand and willing to sign the informed CF

Exclusion Criteria:

• Women of child bearing potential patients must demonstrate a negative pregnancy test
performed within 24 hours before CT